Regnum Corp.
OTC: RGMP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Robert J. Stubblefield
- Employees
- 1
- Headquarters
- New York City, United States
- IPO year
- 2019
- Market cap
- $2.3K
- Website
- https://www.regnumcorp.com
Loading RGMP…
Loading profile data…Frequently asked questions about RGMP
What does Regnum Corp. (RGMP) do?
Regnum Corp. is dedicated to advancing and marketing therapeutic agents designed to combat both rare and infectious diseases. Its flagship product is Leronlimab (PRO 140), a monoclonal antibody functioning as a C-C chemokine receptor type 5 (CCR5) antagonist. This drug is specifically formulated to inhibit the human immunodeficiency virus (HIV)...
Where does RGMP trade?
Regnum Corp. (RGMP) trades on the Other OTC.
What sector is RGMP in?
Regnum Corp. (RGMP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Regnum Corp.?
Robert J. Stubblefield is the chief executive officer of Regnum Corp. (RGMP).
Where is Regnum Corp. headquartered?
Regnum Corp. is headquartered in United States.
Does RGMP pay a dividend?
Regnum Corp. (RGMP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RGMP go public?
Regnum Corp. (RGMP) completed its initial public offering in 2019.